Jan Hartmann, M.D.
@janhartmannmd.bsky.social
150 followers 46 following 77 posts
Bringing Med to MedTech - Physician, Scientist, Photographer, Traveler, Berliner, Immigrant 🇩🇪🇺🇸 - Views=My own, Like/RT≠Endorsement; Haemonetics employee
Posts Media Videos Starter Packs
Reposted by Jan Hartmann, M.D.
nejm.org
Monoclonal gammopathy of undetermined significance is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. Diagnosis warrants follow-up, but treatment is not required unless progression is confirmed. Learn more: nej.md/473uOsj
An illustrated diagram of the pathogenesis and progression of monoclonal gammopathy of undetermined significance (MGUS).
Reposted by Jan Hartmann, M.D.
laskerfdn.bsky.social
“For physician–scientists conducting early clinical trials, the results could best be described as miraculous.” 🧪
2025 #LaskerAward winners M. Welsh, J. González, & P. Negulescu developed life-saving #cysticfibrosis treatments. @nejm.org
#Lasker2025
Transformative Research in Cystic Fibrosis | NEJM
Michael Welsh, Jesús González, and Paul Negulescu have won the 2025 Lasker–DeBakey Clinical Medical Research Award for their roles in developing treatments for cystic fibrosis.
www.nejm.org
Reposted by Jan Hartmann, M.D.
nejm.org
NEJM.org @nejm.org · Sep 3
In patients with heparin-induced thrombocytopenia, pathogenic antibodies were found to be monoclonal, which challenges previous views of HIT as a polyclonal disorder and suggests new avenues for diagnosis and treatment. Full study results: nej.md/4pkaYAq

#MedSky #CardioSky
Figures showing the detection and function of anti–PF4–heparin antibodies from patients with heparin-induced thrombocytopenia.
janhartmannmd.bsky.social
Rainbow over Sandy Bay – Rockport, MA 🌈
Reposted by Jan Hartmann, M.D.
nejm.org
NEJM.org @nejm.org · Jul 13
In the BATURA phase 3b trial, as-needed albuterol–budesonide resulted in a lower risk of severe asthma exacerbation than as-needed albuterol among participants with disease that was uncontrolled despite treatment for mild asthma. Full trial results and Research Summary: nej.md/43uVpwK
The New England Journal of Medicine              
As-Needed Albuterol–Budesonide in Mild Asthma 
A Research Summary based on LaForce C et al. | 10.1056/NEJMoa2504544 | Published on May 19, 2025  

Visual representations of the patients in the trial and the treatments they were assigned.                  

Read the full Research Summary at NEJM.org.
Reposted by Jan Hartmann, M.D.
michaelmina.bsky.social
It’s Code Red for Vaccines

The number of changes to vaccine policy is dizzying & RFK Jr is just getting started!

Dissolving the group of experts that drive policy is declaring war on “what was”

I write in @nytimes.com about what is and is not working

www.nytimes.com/2025/06/11/o...
Opinion | It’s Code Red for Vaccines in America (Gift Article)
How to make sense of all the vaccine policy changes.
www.nytimes.com
Reposted by Jan Hartmann, M.D.
nature.com
Nature @nature.com · Jun 10
This tiny device can shrink dangerous blood clots. It’s called the ‘milli-spinner’ and its invention was partly an accident…
janhartmannmd.bsky.social
2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP url:https://academic.oup.com/ejcts/article/67/5/ezae352/7815985
janhartmannmd.bsky.social
Public radio in Boston… 📻 ⁦‪ ⁦‬⁩ #BumpaSticka @npr.org @wbur.org
Reposted by Jan Hartmann, M.D.
nejm.org
NEJM.org @nejm.org · May 2
For a woman with device-detected atrial fibrillation, would you initiate anticoagulant therapy or recommend continuation of antiplatelet therapy? Read the case vignette and essays on both treatment options and cast your vote: nej.md/4lQzxTA

#MedSky #CardioSky #Afib
CLINICAL DECISIONS 
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation 

An illustration of a smartwatch monitoring ECG and two bottles, one containing an anticoagulant, and the other containing aspirin